A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Daratumumab (Primary) ; Hyaluronidase
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Aug 2017 New trial record